Image source: The Motley Fool.
Allogene Therapeutics Inc (NASDAQ: ALLO)
Q3 2021 Earnings Call
Nov 4, 2021 , 5:00 p.m. ET
Operator
For further details see:
Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call TranscriptImage source: The Motley Fool.
Allogene Therapeutics Inc (NASDAQ: ALLO)
Q3 2021 Earnings Call
Nov 4, 2021 , 5:00 p.m. ET
Operator
For further details see:
Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
Market:
Allogene Therapeutics Inc. Website:
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Dat...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing Technology First Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 20...